Skip to main content

Table 1 Patient characteristics

From: Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation

Clinical Features n (%)
Age (y)
 62.4 ± 9
 Range (42–88)
Sex
 F 32 (23.9%)
 M 102 (76.1%)
Grade of differentiation
 Highly differentiated (G1) 12 (9.0%)
 Moderately differentiated(G2) 95 (70.9%)
 Poorly differentiated(G3) 22 (16.4%)
 Undifferentiated (G4) 5 (3.7%)
Primary tumor site
 Cervical 13 (9.7%)
 Upper thorax 44 (32.8%)
 Middle thorax 60 (44.8%)
 Lower thorax 14 (10.4%)
 Mixed 3 (2.2%)
Length of primary tumor
  < 3.5 27(20.2%)
  > 3.5 104 (77.6%)
 Not available 3 (2.2%)
*T stage
 T1 3 (2.2%)
 T2 8 (6.0%)
 T3 43 (32.1%)
 T4 80 (59.7%)
*N stage
 N0 49 (36.6%)
 N1 50 (37.3%)
 N2 35 (26.1%)
Concurrent chemotherapy
 No 48 (35.8%)
 Yes 86 (64.2%)
  1. *TNM staging was determined based on the Clinical non operative treatment of esophageal cancer staging criteria (draft, 2010)